Quick Guide to YCANTH® Access & Reimbursement

Important Billing & Coding Information for YCANTH

PERMANENT J-CODE (J7354)	DESCRIPTION
	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)

CPT CODE (17110)	DESCRIPTION
	14 LESIONS OR LESS Destruction (e.g., laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions up to 14 lesions

CPT CODE (17111)	DESCRIPTION
	15 LESIONS OR GREATER Destruction (e.g., laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions 15 or more lesions

⚠ The **ICD 10 code is B08.1** for Molluscum Contagiosum.

YcanthRx™ support

One-stop Support for Patients and Practicing Physicians

Once patients are fully enrolled in YcanthRx Support, dedicated case managers support healthcare providers and patients throughout the access process, whether through buy-and-bill or specialty pharmacy.

- Prior Authorization (and submission if applicable)
- Pre Determination
- Billing and Coding Support
- YCANTH Copay Program Enrollment
- Prescription Triage
- Dedicated Case Managers

www.YcanthRXPortal.com | Phone: 1-855-922-6847 **| Fax:** 1-844-922-6847
Monday - Friday 8:00am to 8:00pm EST

Indication

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

Important Safety Information

CONTRAINDICATIONS: None.

VERRICA PHARMACEUTICALS

See Important Safety Information and Full Prescribing Information at YCANTHPro.com

Patent: www.verrica.com/patents

YCANTH and Y-Access are registered trademarks of Verrica Pharmaceuticals Inc.
Copyright © 2026 Verrica Pharmaceuticals Inc. All right reserved. (10/26) US-YCN-00111

Ycanth® (cantharidin) TOPICAL SOLUTION 0.7%

Quick Guide to YCANTH® Access & Reimbursement

Important Safety Information (continued)

WARNINGS AND PRECAUTIONS:

- YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
- Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
- YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.